Toward repurposing drugs for CSC inhibition, we initially screened an NCI Diversity library of FDA-approved drugs using H460 human lung cancer cell line which contains mutations in the clinically relevant genes EGFR and KRAS (Fig. S4). Here, KRAS is linked to lung carcinoma.